Boundless Bio Statistics

Total Valuation

Boundless Bio has a market cap or net worth of $26.19 million. The enterprise value is -$51.45 million.

Market Cap	26.19M
Enterprise Value	-51.45M

Important Dates

The last earnings date was Tuesday, August 5, 2025, before market open.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Boundless Bio has 22.38 million shares outstanding. The number of shares has increased by 246.75% in one year.

Current Share Class	22.38M
Shares Outstanding	22.38M
Shares Change (YoY)	+246.75%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	1.72%
Owned by Institutions (%)	48.20%
Float	14.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.21
P/TBV Ratio	0.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.08, with a Debt / Equity ratio of 0.40.

Current Ratio	14.08
Quick Ratio	13.80
Debt / Equity	0.40
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -42.65% and return on invested capital (ROIC) is -25.33%.

Return on Equity (ROE)	-42.65%
Return on Assets (ROA)	-24.27%
Return on Invested Capital (ROIC)	-25.33%
Return on Capital Employed (ROCE)	-41.94%
Revenue Per Employee	n/a
Profits Per Employee	-$1.01M
Employee Count	64
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -59.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-59.38%
50-Day Moving Average	1.13
200-Day Moving Average	1.89
Relative Strength Index (RSI)	50.98
Average Volume (20 Days)	83,310

Short Selling Information

The latest short interest is 99,719, so 0.45% of the outstanding shares have been sold short.

Short Interest	99,719
Short Previous Month	75,423
Short % of Shares Out	0.45%
Short % of Float	0.70%
Short Ratio (days to cover)	0.95

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-71.40M
Pretax Income	n/a
Net Income	-64.39M
EBITDA	-70.20M
EBIT	-71.40M
Earnings Per Share (EPS)	-$2.88

Full Income Statement

Balance Sheet

The company has $127.15 million in cash and $49.51 million in debt, giving a net cash position of $77.64 million or $3.47 per share.

Cash & Cash Equivalents	127.15M
Total Debt	49.51M
Net Cash	77.64M
Net Cash Per Share	$3.47
Equity (Book Value)	122.69M
Book Value Per Share	5.48
Working Capital	120.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$55.19 million and capital expenditures -$1.06 million, giving a free cash flow of -$56.24 million.

Operating Cash Flow	-55.19M
Capital Expenditures	-1.06M
Free Cash Flow	-56.24M
FCF Per Share	-$2.51

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Boundless Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-246.75%
Shareholder Yield	-246.75%
Earnings Yield	-245.86%
FCF Yield	-214.76%

Analyst Forecast

The average price target for Boundless Bio is $4.00, which is 241.88% higher than the current price. The consensus rating is "Buy".

Price Target	$4.00
Price Target Difference	241.88%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1